ASCO 2018 Annual Meeting Highlights in Multiple Myeloma
Release Date: July 25, 2018
Expiration Date: July 25, 2019
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
In this activity, leading multiple myeloma investigators will present key highlights of several significant scientific updates in multiple myeloma presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. View video from the meeting and listen as they share their insights on a variety of abstracts, covering topics including, but not limited to: combination therapy with triplet and quadruplet regimens, immunotherapy, and safety and efficacy profiles of various treatment options in the upfront and relapsed/refractory settings.
This activity includes notable highlights in the ALCYONE (daratumumab), ELOQUENT-2 (elotuzumab), and OPTIMISMM (pomalidomide) trials among others, as well as developments in CAR T cell therapy in myeloma. Don’t miss this opportunity to see how the future of treatment in myeloma is continuing to evolve, and how these changes may positively impact patient outcomes.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurses, pharmacists and other allied healthcare professionals who provide care to patients with multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Summarize the efficacy and safety data from clinical trials investigating novel therapies and treatment strategies in patients with multiple myeloma
- Describe expert faculty perspectives on key clinical trial data for novel therapies and treatment strategies in multiple myeloma
- Recognize the potential impact of clinical trials on clinical practice and existing treatment paradigms in multiple myeloma
ASCO Overview from Saad Z. Usmani, MD, FACP
- Dr. Usmani reviews key findings and trials to watch
ASCO Highlights from Noopur Raje, MD
- bb2121 anti-BCMA CAR T cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study (8007)
- Phase II study of ex vivo expanded cord blood natural killer cells for multiple myeloma (8006)
- FDA analysis of pembrolizumab trials in multiple myeloma: Immune related adverse events (irAEs) and response (8008)
ASCO Highlights from Sagar Lonial, MD, FACP
- A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma (8012)
- Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab + lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM) (8040)
- Daratumumab plus bortezomib-melphalan-prednisone (VMP) in elderly (≥75 y) patients (Pts) with newly diagnosed multiple myeloma (NDMM) ineligible for transplantation (ALCYONE) (8031)
- Randomized, open-label, phase 3 study of subcutaneous daratumumab (DARA SC) versus active monitoring in patients (Pts) with high-risk smoldering multiple myeloma (SMM): AQUILA (TPS8062)
ASCO Highlights from Saad Z. Usmani, MD, FACP
- A phase 3 randomized study of pembrolizumab (pembro) plus lenalidomide (len) and low-dose dexamethasone (Rd) versus Rd for newly diagnosed and treatment-naive multiple myeloma (MM): KEYNOTE-185 (8010)
- Subcutaneous daratumumab (DARA) in patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Part 2 update of the open-label, multicenter, dose escalation phase 1b study (PAVO) (8013)
- Randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients with relapsed or refractory multiple myeloma (RRMM): COLUMBA (TPS8058)
- Final results of a phase Ib study of isatuximab (ISA) plus pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM) (8038)
- Pomalidomide (POM), bortezomib, and low‐dose dexamethasone (PVd) vs bortezomib and low-dose dexamethasone (Vd) in lenalidomide (LEN)-exposed patients (pts) with relapsed or refractory multiple myeloma (RRMM): Phase 3 OPTIMISMM trial (8001)
ASCO Highlights from Robert Z. Orlowski, MD, PhD
- Carfilzomib and dexamethasone (Kd56) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): Updated overall survival (OS), safety, and subgroup analysis of ENDEAVOR (8032)
- Phase III (IKEMA) study design: Isatuximab plus carfilzomib and dexamethasone (Kd) vs Kd in patients with relapsed/refractory multiple myeloma (RRMM) (TPS8060)
- Phase III (IMROZ) study design: Isatuximab plus bortezomib (V), lenalidomide (R), and dexamethasone (d) vs VRd in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM) (TPS8055)
Instructions for Participation and Credit
This activity is eligible for credit through July 25, 2019. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Dr. Sagar Lonial earned his medical degree from the University of Louisville School of Medicine. He completed his internship and residency at Baylor College of Medicine in Houston, Texas, followed by a fellowship in hematology/oncology at Emory University School of Medicine in Atlanta, Georgia. He is the Department Chair for Hematology and Medical Oncology at Emory University.
Dr. Lonial serves as Vice Chair of the Myeloma Committee in the Eastern Cooperative Oncology Group and as Chair of the Steering Committee for the Multiple Myeloma Research Consortium. Additionally, he is on the Board of Directors for the International Myeloma Society and on the Scientific Advisory Board for the International Myeloma Foundation. Dr. Lonial is the myeloma editor for Clinical Lymphoma and Myeloma and is on the editorial board for the Journal of Clinical Oncology. He is also an ad hoc reviewer for Blood, Cancer Research, Clinical Cancer Research, Haematologica, Leukemia, and other journals, and has authored or co-authored over 200 papers and abstracts.
Dr. Lonial has worked in the field of immunotherapy and cancer, and has spent time developing the B-cell malignancy program with respect to novel targeted agents in laboratory models as well as early clinical trials. His previous laboratory work has focused on evaluating the impact of purified dendritic cell subsets on the nature of immune responses against antigen. Most recently, Dr. Lonial has focused on combinations of novel agents as therapy for myeloma and lymphoma, particularly evaluating combinations that may result in synergistic inhibition of the PI3-K/Akt pathway and the role of 14-3-3 in proteasome function.
Robert Z. Orlowski, MD, PhD
Professor, Chair Ad Interim
Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Dr. Robert Orlowski earned his doctoral degree in molecular biophysics and biochemistry from Yale University and his medical degree from the Yale University School of Medicine. He completed his internship and residency in internal medicine at Barnes Hospital at Washington University, St. Louis School of Medicine. Dr. Orlowski is a Professor and Chair Ad Interim in the Department of Lymphoma/Myeloma, and Professor in the Department of Experimental Therapeutics, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.
Board-certified in internal medicine and medical oncology, Dr. Orlowski has published numerous book chapters, articles, and abstracts on cancer therapy with a focus on the pathogenesis of oncologic disease and mechanisms of action of chemotherapeutics. In addition, he is a reviewer for several journals, including Blood, Cancer Research, Journal of Clinical Oncology, and The New England Journal of Medicine. His clinical research efforts focus on novel clinical trials for patients with hematologic malignancies.
Noopur Raje, MD
Professor of Medicine
Harvard Medical School
Director, Center for Multiple Myeloma
Massachusetts General Hospital
Dr. Noopur Raje received her medical degree from B.J. Medical College, Pune University in India. She trained in internal medicine at Massachusetts General Hospital (MGH), and subsequently completed a fellowship in hematology and medical oncology in the joint Mass General-Brigham & Women’s-Dana-Farber program. She is a Professor of Medicine at Harvard Medical School and the Rita M. Kelley Chair in Oncology at MGH.
Dr. Raje is a physician scientist with a focus on the development of innovative therapies for multiple myeloma. As Director of the Center for Multiple Myeloma at the MGH Cancer Center, she leads a dedicated clinical team engaged in investigator-initiated, multicenter national and international clinical trials, all aimed at developing new promising therapies for this disease. She also leads translational efforts at MGH with her laboratory's efforts focused on identifying cellular signaling pathways that contribute to the survival and proliferation of myeloma cells in the bone environment, and whose targeting may result in improved therapeutic outcomes. Dr. Raje is the recipient of numerous awards including the Multiple Myeloma Senior Research Award, The Leukemia and Lymphoma Society Clinical Scholar Award and the Claflin Distinguished Scholar Award.
Saad Z. Usmani, MD, FACP
Chief, Plasma Cell Disorders Program
Director, Clinical Research in Hematologic Malignancies
Levine Cancer Institute/Atrium Health
Charlotte, North Carolina
Clinical Professor of Medicine, UNC-Chapel Hill School of Medicine
Chapel Hill, North Carolina
Dr. Saad Usmani received his medical education at Allama Iqbal Medical College Lahore, Pakistan. He completed a residency in internal medicine at Sinai-Grace Hospital/Wayne State University in Detroit, Michigan, and a fellowship in hematology and oncology at the University of Connecticut Health Center in Farmington, Connecticut. Dr. Usmani is a Clinical Professor of Medicine at the UNC School of Medicine, Chief of the Plasma Cell Disorder Program, and Director of Clinical Research in Hematologic Malignancies at the Levine Cancer Institute/Atrium Health.
Dr. Usmani is a member of the International Myeloma Working Group, SWOG Myeloma Committee, American Society of Hematology (ASH), American Society of Clinical Oncology (ASCO), and the American Society of Bone Marrow Transplantation. He has served on the ASCO Scientific Committee on Lymphoma and Plasma Cell Disorders, the ASH Committee on Plasma Cell Neoplasia, and the NCI Myeloma Steering Committee. Dr. Usmani is on the editorial review board of numerous medical journals, has authored/co-authored more than 80 peer-reviewed research manuscripts and 100 abstracts at national and international meetings. A specialist in hematology, medical oncology and bone marrow transplantation, Dr. Usmani’s clinical and translational research has been focused on plasma cell disorders, specifically high-risk multiple myeloma.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-18-015-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 18-015-076
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Sagar Lonial has received honoraria as a consultant from Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novartis AG, and Takeda Oncology.
Dr. Robert Orlowski has received honoraria related to formal advisory activities from Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Janssen Pharmaceuticals, Inc., Kite Pharma, sanofi-aventis U.S. LLC., and Takeda Oncology. He has received grant support related to research activities from Amgen, BioTheryX, Inc., and Spectrum Pharmaceuticals, Inc.
Dr. Noopur Raje has received honoraria as a consultant from Amgen Inc., Celgene Corporation, Onyx Pharmaceuticals, Inc., an Amgen subsidiary, and Takeda Oncology.
Dr. Saad Usmani has received honoraria related to formal advisory activities from AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Janssen Pharmaceuticals, Merck & Co., Inc., Seattle Genetics, Inc., Takeda Oncology, and TeneoBio, as well as speakers’ bureau activities from Amgen, Celgene, Janssen, and Takeda Oncology. He has received grant support related to research activities from AbbVie Inc., Amgen, Bristol-Myers Squibb Company, Celgene, Janssen, Pharmacyclics, Inc., Sanofi. Seattle Genetics, Inc., and Takeda Oncology.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Kristin Burke, Project Manager, Keith D’Oria, Medical Writer, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen, Bristol-Myers Squibb, Celgene Corporation, and Takeda Oncology
©2018 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.